Search

everythinglearnresearchcommunity

for

Search:↓

Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.

New treatments for seborrheic dermatitis show promise for difficult cases.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.